Fertility and consumer‑genetics startups are moving beyond disease screening to sell polygenic trait predictions for embryos (height, BMI, ADHD risk, IQ points). These products turn statistical adult predictors into consumer‑facing embryo reports that prospective parents can use to choose among IVF embryos.
— If scaled, commercial embryo trait‑scoring will force policy choices on regulation, equity, reproductive commercialization, and whether small probabilistic trait advantages become inherited status goods.
2026.04.04
88% relevant
This is a direct fit: the article profiles a startup (Herasight) selling embryo‑selection products claiming higher IQ and lower disease risk, which maps onto the trend of commercial firms offering polygenic embryo scoring and the attendant scrutiny over claims and impacts.
2026.04.04
100% relevant
The article names Nucleus and Herasight partnering with Genomic Prediction and advertising an IQ predictor worth ~6–9 points and trait outputs (height, eye color, ADHD), showing the concrete market shift.
← Back to All Ideas